United Therapeutics (NASDAQ:UTHR) has been given a $160.00 target price by research analysts at Oppenheimer in a research note issued to investors on Tuesday. The firm presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s target price suggests a potential upside of 37.30% from the company’s current price.

Several other analysts also recently commented on the stock. Credit Suisse Group restated an “underperform” rating and set a $98.00 price objective (down from $105.00) on shares of United Therapeutics in a research report on Tuesday. BidaskClub upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, March 22nd. Barclays decreased their price objective on shares of United Therapeutics from $100.00 to $95.00 and set an “underweight” rating on the stock in a research report on Friday, March 1st. LADENBURG THALM/SH SH set a $124.00 price target on shares of United Therapeutics and gave the company a “hold” rating in a report on Thursday, February 28th. Finally, Cowen reiterated a “hold” rating and issued a $109.00 price target on shares of United Therapeutics in a report on Wednesday, February 27th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $131.89.

UTHR opened at $116.53 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.03 and a current ratio of 6.39. United Therapeutics has a 1-year low of $100.06 and a 1-year high of $130.00. The company has a market capitalization of $5.26 billion, a price-to-earnings ratio of 8.70, a price-to-earnings-growth ratio of -1.85 and a beta of 1.11.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported $1.48 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.19 by ($0.71). The firm had revenue of $381.40 million for the quarter, compared to the consensus estimate of $355.81 million. United Therapeutics had a net margin of 36.20% and a return on equity of 22.63%. The firm’s revenue for the quarter was down 17.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.89 earnings per share. On average, equities analysts anticipate that United Therapeutics will post 9.28 EPS for the current year.

In other United Therapeutics news, Director Christopher Patusky sold 3,370 shares of United Therapeutics stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $110.75, for a total value of $373,227.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Tommy G. Thompson sold 400 shares of United Therapeutics stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $117.00, for a total transaction of $46,800.00. Following the completion of the sale, the director now owns 2,970 shares in the company, valued at $347,490. The disclosure for this sale can be found here. Over the last quarter, insiders sold 102,527 shares of company stock worth $11,695,041. 8.20% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Captrust Financial Advisors grew its stake in shares of United Therapeutics by 384.9% in the 4th quarter. Captrust Financial Advisors now owns 257 shares of the biotechnology company’s stock worth $28,000 after buying an additional 204 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of United Therapeutics by 10,537.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 3,551,229 shares of the biotechnology company’s stock worth $33,000 after buying an additional 3,517,845 shares in the last quarter. First Mercantile Trust Co. grew its stake in shares of United Therapeutics by 47.8% in the 4th quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock worth $37,000 after buying an additional 110 shares in the last quarter. Financial Gravity Companies Inc. purchased a new position in shares of United Therapeutics in the 4th quarter worth $44,000. Finally, Daiwa Securities Group Inc. grew its stake in shares of United Therapeutics by 13.2% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,799 shares of the biotechnology company’s stock worth $196,000 after buying an additional 210 shares in the last quarter. Institutional investors own 97.65% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Article: What is the float in trading stocks?

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.